Thursday, January 5, 2012

Thyrosafe (20Tablets) FDA approved Potassium Iodide 65mg

Thyrosafe (20Tablets) FDA approved Potassium Iodide 65mg Review



Protect your thyroid gland against radiation. ThyroSafe is the only FDA approved 65 mg. Potassium Iodide (KI) tablet. It is used to protect your thyroid gland against radioactive iodine released during a nuclear emergency. It does this by flooding the thyroid with stable, safe iodine, which blocks the absorption of dangerous radioactive iodine. ThyroSafeTM is produced by Recipharm AB who has more than 20 years experience in manufacturing Potassium Iodide tablets. Each tablet of ThyroSafeTM has a convenient cross-score, making it easy to break for small children.

Emergency government stock piles of potassium iodide are only available in limited supplies in Alabama, Arizona, Maine, and Tennessee. In NY and NJ some tablets have been handed out to residents closest to Nuclear power plants.Analysing the data from the Chernobyl nuclear disaster it is evident that the government does not have the ability to provide protection in the event of a nuclear disaster.Studies have shown that "thyroid damage can be a concern more than 200 miles downwind from a nuclear accident. Emergency planning which focuses on areas close to nuclear power plants is not sufficient." Evacuation is still the main component of the governments plant to protect the public. We all know that evacuation will not work in most circumstances. Fallout from Chernobyl was first detected over 300 miles from the accident site. If you live within 300 miles of a nuclear power plant, ThyroSafeTM can protect your family from the effects of radioactive fallout.

FDA Recommended Dose

Age 18+ - 130mg daily (2 tablets)

Age 3-18 - 65mg daily (1 tablet)

1 month to 3 yrs. - 32mg daily (½ tablet)

Birth to 1 month - 16mg daily (¼ tablet)

Potassium Iodide (KI) must be taken prior to or soon after exposure of radiation from nuclear fallout in order to be effective, therefore Potassium Iodide must be readily on-hand.


No comments:

Post a Comment